Submitted by Anonymous (not verified) on 3 July 2026 - 15:00
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 15, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 15, Status: Authorised